Pharma Outpaces All Other Industries In US Federal Lobbying Spending
Over the past 20 years, the pharmaceutical industry has notched a series of wins with its extraordinary federal lobbying expenditures and campaign contributions. A new JAMA Internal Medicine study examines spending from 1999-2018.
You may also be interested in...
JAMA Drug Pricing Studies: Moving The Needle Or Looking At The Past?
Studies show net prices increases, R&D spending lower than often cited, and better profit margins other industries. But pharma pushes back with concerns about study designs and maintains the picture has changed in more recent years.
The Cost To Bring A New Drug To Market? $1.3bn, JAMA Study Finds
The mean R&D investment required to bring a new drug to market was $1.3bn in a new study estimating pharma R&D costs, lower than the $2.8bn frequently cited from a prior study.
Both US List And Net Drug Price Increases Have Been Substantial, JAMA Study Finds
A new study looks at list drug price increases and manufacturer discounts over 11 years and finds that despite significant rebates, net price increases still grew 3.5 times more than inflation.